U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07328425) titled 'Phase II Study in Adult and Young Adult Patients With DSRCT' on Nov. 17, 2025.
Brief Summary: This study involves patients with the same type of advanced cancer as you-DSRCT, a very rare soft tissue sarcoma.
Patients participating in this study have DSRCT that has spread locally or to other parts of the body and can no longer be surgically removed without causing significant harm.
Participants will receive a combination of lurbinectedin and irinotecan. Treatment will continue until the tumor progresses further, severe side effects occur, or either patient or investigator decision.
In addition, patients may participate in an optio...